NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 31, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=110017&fro ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/elanco-animal-h ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=109662 ...

文章核心观点 - 领先的证券法律事务所Bleichmar Fonti & Auld LLP宣布已对Elanco Animal Health Incorporated(纽交所代码:ELAN)及其高管提起诉讼,指控其可能违反联邦证券法 [1][2] - Elanco公司开发用于治疗动物疾病的产品,其两款重要的研发管线产品正在等待美国FDA审批,但公司此前表示FDA已有所有数据完成审查,预计2024年6月前获批,但后来公司宣布FDA将不会在6月批准这两款药品,其中一款还将带有安全警示 [3][4] - 由于这一消息,Elanco股价在2024年6月27日下跌超过21% [5] 公司概况 - Elanco Animal Health Incorporated是一家专注于动物健康的公司,主要开发用于治疗动物疾病的产品 [3] - 公司两款重要的研发管线产品分别是Zenrelia(治疗犬类皮肤炎)和Credelio Quattro(广谱口服驱虫药,可预防跳蚤、蜱和内寄生虫) [3] 监管审批情况 - 公司此前表示FDA已有所有数据完成审查,预计2024年6月前获批 [4] - 但后来公司宣布FDA将不会在2024年6月批准这两款药品,其中一款Zenrelia还将带有安全警示 [4] 股价影响 - 由于Elanco公司发布的上述消息,其股价在2024年6月27日下跌超过21%,从前一交易日的17.97美元下跌至14.27美元 [5]

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/elanco-animal-health- ...

SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- A federal lawsuit has been filed in the U.S. District Court of Maryland against Elanco Animal Health Inc. and specific executives, accusing them of making false and misleading statements between November 7, 2023, and June 26, 2024. Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now. Class Period: Nov. 7, 2023 – June 26, 2024Lead Plaintiff Deadline: Dec. 6, 2024 Visit: www.hbss ...

NEW YORK, Oct. 28, 2024 The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN).Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=109386&from=4CLASS PERIOD: Nov ...

文章核心观点 - 根据诉讼,在Class Period期间,被告做出了虚假和/或误导性陈述,和/或未能披露:(1)Zenrelia(一种每日一次的口服Janus激酶(JAK)抑制剂,用于犬皮肤病)的安全性低于Elanco向投资者披露的程度[1][2][3];(2)Elanco不太可能达到自己此前发布的Zenrelia和Credelio Quattro(一种犬用广谱驱虫产品)在美国获批和上市的时间表[1][2][3];(3)因此,Elanco的业务和/或财务前景被夸大了[1][2][3];(4)因此,Elanco的公开声明在所有相关时期都存在重大虚假和误导性[1][2][3]。当真相进入市场时,诉讼称投资者遭受了损失[1][2][3]。 公司相关 - Elanco Animal Health Incorporated是一家动物保健公司,在纽约证券交易所上市,股票代码为ELAN[1] - Zenrelia是Elanco开发的一种每日一次的口服Janus激酶(JAK)抑制剂,用于犬皮肤病[1][2][3] - Credelio Quattro是Elanco开发的一种犬用广谱驱虫产品[1][2][3] 投资者诉讼相关 - 罗森律师事务所代表在2023年11月7日至2024年6月26日期间(包括首尾两日)购买Elanco证券的投资者提起集体诉讼[1] - 集体诉讼的重要截止日期为2024年12月6日,投资者如果在此期间购买了Elanco证券,可能有权获得赔偿,无需支付任何费用[1] - 如果投资者希望担任首席原告,必须在2024年12月6日之前向法院提出申请[1]

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...